JPRN-jRCT2080222684未知2 期
DS-7113b injection phase II/III study An open label and extension study of DS-7113 injection in patients with cancer pain (intravenous administration)
DAIICHISANKYO Co.,Ltd.0 个研究点开始时间: 2014年12月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who can be hospitalized during a dosage period, and secure a route to carry out intravenous administration
- •2) Patients receiving analgesics for cancer pain
- •3) Patients with an ECOG Performance Status (PS) is =< 3, etc.
排除标准
- •Patients with symptom(s)/finding(s) falling under the contraindications or relative contraindications stated in the package insert for oral oxycodone hydrochloride and morphine hydrochloride, etc.
研究者
相似试验
未知
2 期
DS-7113b injection phase II/III study (subcutaneous injection)JPRN-jRCT2080222685DAIICHISANKYO Co.,Ltd.
未知
3 期
DS-7113b phase III studyModerate to severe cancer painJPRN-jRCT2080222239DAIICHISANKYO Co.,Ltd.
未知
2 期
DS-7113b phase II studyModerate to severe cancer painJPRN-jRCT2080222120DAIICHISANKYO Co.,Ltd.
未知
3 期
DS-7113b phase III studyModerate to severe cancer painJPRN-jRCT2080222289DAIICHISANKYO Co.,Ltd.
未知
1 期
Phase I study of DS-7113bHealthy volunteersJPRN-jRCT2080222121DAIICHISANKYO Co.,Ltd.30